|
gptkbp:instanceOf
|
drug
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Tykerb
|
|
gptkbp:chemicalFormula
|
C29H26ClN3O4S
|
|
gptkbp:clinicalTrials
|
Phase II
Phase III
treatment of breast cancer
treatment of HER2-positive tumors
treatment of advanced cancer
|
|
gptkbp:compatibleWith
|
approximately 25%
|
|
gptkbp:contraindication
|
liver disease
pregnancy
breastfeeding
|
|
gptkbp:date
|
2007
|
|
gptkbp:developedBy
|
gptkb:GlaxoSmithKline
|
|
gptkbp:drugInterdiction
|
targeted therapy
antineoplastic agent
small molecule
|
|
gptkbp:endOfLife
|
approximately 24 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lapatinib
|
|
gptkbp:isATypeOf
|
231277-16-0
|
|
gptkbp:issuedBy
|
oral tablet
|
|
gptkbp:lastProduced
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mandates
|
metastatic breast cancer
advanced breast cancer
|
|
gptkbp:marketedAs
|
gptkb:Tykerb
|
|
gptkbp:nutritionalValue
|
liver
|
|
gptkbp:operates_in
|
L01XE05
|
|
gptkbp:patentStatus
|
patented
|
|
gptkbp:researchAreas
|
drug development
oncology
pharmacology
clinical research
|
|
gptkbp:sideEffect
|
fatigue
nausea
diarrhea
rash
heart problems
|
|
gptkbp:targets
|
gptkb:EGFR
HER2
|
|
gptkbp:triggerType
|
tyrosine kinase inhibitor
|
|
gptkbp:type
|
gptkb:Lapatinib
|
|
gptkbp:usedFor
|
breast cancer
HER2-positive breast cancer
|
|
gptkbp:variant
|
gptkb:letrozole
trastuzumab
capecitabine
|
|
gptkbp:waterManagement
|
urine
feces
|